TCL Archive Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden By Cancer History Project July 26, 2013
TCL Archive ASCO Recommends Discussing Pharmacological Prevention By Cancer History Project July 26, 2013
TCL Archive Elderly and Younger Patients Have Similar Outcomes Following Radioembolization By Cancer History Project July 26, 2013
TCL Archive Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness By Cancer History Project July 26, 2013
TCL Archive Statistical Models Determine Stem-Cell Transplant Effectiveness By Cancer History Project July 26, 2013
TCL Archive Phase II Elotuzumab Study Demonstrates 33 Months PFS By Cancer History Project July 26, 2013
TCL Archive Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study By Cancer History Project July 26, 2013
TCL Archive Biomarker Test Outperforms PSA and Gleason Score in Study By Cancer History Project July 26, 2013
Primary SourceSpotlight Article Iressa: Oncologic Drugs Advisory Committee Meeting Sept. 24, 2002 By FDA Oncology Center of Excellence
Primary SourceSpotlight Article Waun Ki Hong, M.D. Oral History Interview, 2013 By MD Anderson Cancer Center